1. Market Research
  2. > Healthcare
  3. > Pathology Market Trends
  4. > Pandemic Influenza-Pipeline Insights, 2016

Pandemic Influenza-Pipeline Insights, 2016

  • November 2016
  • -
  • Delve Insight
  • -
  • 60 pages


DelveInsight’s, “ Pandemic Influenza-Pipeline Insights, 2016”, report provides in depth insights on the pipeline drugs and their development activities around the Pandemic Influenza. The DelveInsight’sReport covers the product profiles in various stages of development including Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration. Report covers the product clinical trials information and other development activities including technology, licensing, collaborations, acquisitions, fundings, patent and USFDA & EMA designations details. DelveInsight’s Report also provides detailed information on the discontinued and dormant drugs that have gone inactive over the years for Pandemic Influenza. DelveInsight’s Report also assesses the Pandemic Influenza therapeutics by Monotherapy, Combination products, Molecule type and Route of Administration.

Please note:This report requires certain updates. We have all the information available but require 3 business days to complete the process and ensure it is as up-to-date as possible. Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated indication.

Scope
- The report provides competitivepipeline landscape of Pandemic Influenza
- The report provides pipeline products under drug profile section which includes product description, MOA, licensors & collaborators, development partner and chemical information
- Coverage of the Pandemic Influenza pipeline on the basis of target, MOA, route of administration, technology involved and molecule type
- The report reviews key players involved in the therapeutics development for Pandemic Influenza and also provide company profiling
- The report also gives the information of dormant and discontinued pipeline projects
- Pipeline products coverage based on various stages of development ranging from preregistration till discovery and undisclosed stages
- Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type

Table Of Contents

Pandemic Influenza-Pipeline Insights, 2016

Illustrative Table of contents

- Pandemic Influenza Overview
- Pandemic Influenza Pipeline Therapeutics
- Pandemic Influenza Therapeutics under Development by Companies
- Pandemic Influenza Filed and Phase III Products
- Comparative Analysis
- Pandemic Influenza Phase II Products
- Comparative Analysis
- Pandemic Influenza Phase I and IND Filed Products
- Comparative Analysis
- Pandemic Influenza Discovery and Pre-Clinical Stage Products
- Comparative Analysis
- Drug Candidate Profiles
- Pandemic Influenza - Therapeutics Assessment
- Assessment by Monotherapy Products
- Assessment by Combination Products
- Assessment by Route of Administration
- Assessment by Molecule Type
- Pandemic Influenza - Discontinued Products
- Pandemic Influenza - Dormant Products
- Companies Involved in Therapeutics Development for Pandemic Influenza
- Appendix
- Methodology
- Contact Us
- Disclaimer

List of Tables

- Number of Products under Development for Pandemic Influenza, 2016
- Number of Products under Development by Companies
- Comparative Analysis by Filed and Phase III Products, 2016
- Comparative Analysis Phase II Products, 2016
- Comparative Analysis Phase I and IND Filed Products, 2016
- Comparative Analysis Discovery and Pre-Clinical Stage Products, 2016
- Drug Candidates Profiles
- Pandemic Influenza Assessment by Monotherapy Products
- Pandemic Influenza Assessment by Combination Products
- Pandemic Influenza Assessment by Route of Administration
- Pandemic Influenza Assessment by Stage and Route of Administration
- Pandemic Influenza Assessment by Molecule Type
- Pandemic Influenza Assessment by Stage and Molecule Type
- Pandemic Influenza Therapeutics - Discontinued Products
- Pandemic Influenza Therapeutics - Dormant Products
- Products under Development by Companies, 2016

List of Figures

- Number of Products under Development for Pandemic Influenza, 2016
- Filed and Phase III Products, 2016
- Phase II Products, 2016
- Phase I and IND Filed Products, 2016
- Discovery and Pre-Clinical Stage Products, 2016
- Pandemic Influenza Assessment by Monotherapy Products
- Pandemic Influenza Assessment by Combination Products
- Pandemic Influenza Assessment by Route of Administration
- Pandemic Influenza Assessment by Stage and Route of Administration
- Pandemic Influenza Assessment by Molecule Type
- Pandemic Influenza Assessment by Stage and Molecule Type

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Influenza Diagnostics Market By Test Type, By End Use and Segment Forecasts to 2024

Influenza Diagnostics Market By Test Type, By End Use and Segment Forecasts to 2024

  • $ 4950
  • Industry report
  • September 2016
  • by Grand View Research

The influenza diagnostics market is expected to reach USD 3.3 billion by 2024, according to a new report by Grand View Research, Inc. Influenza, or "the flu," is an infectious disease and affects the uppe ...

H1N1 (Swine Influenza)- Market Insights, Epidemiology and Market Forecast-2023

H1N1 (Swine Influenza)- Market Insights, Epidemiology and Market Forecast-2023

  • $ 4950
  • Industry report
  • November 2016
  • by Delve Insight

Note*: This report requires 5 business days to complete. DelveInsight’s H1N1 (Swine Influenza) - Market Insights, Epidemiology and Market Forecast-2023” Reports provides an overview of the disease ...

Influenza Diagnostics Market By Test Type (Rapid Influenza Diagnostic Test [RIDT], Reverse Transcription Polymerase Chain Reaction[RT-PCR], Cell Culture, Others - Immunofluorescence, Serology), By End Use, And Segment Forecasts To 2024

Influenza Diagnostics Market By Test Type (Rapid Influenza Diagnostic Test [RIDT], Reverse Transcription Polymerase Chain Reaction[RT-PCR], Cell Culture, Others - Immunofluorescence, Serology), By End Use, And Segment Forecasts To 2024

  • $ 4950
  • Industry report
  • September 2016
  • by Grand View Research

The influenza diagnostics market is expected to reach USD 3.3 billion by 2024, according to a new report by Grand View Research, Inc. Influenza, or "the flu," is an infectious disease and affects the uppe ...


Download Unlimited Documents from Trusted Public Sources

Infectious Disease Statistics and Anti-Infective Market in the UK

  • November 2016
    11 pages
  • Infectious Dise...  

    Anti-Infective  

  • United Kingdom  

View report >

Lung Cancer Statistics in the US

  • November 2016
    25 pages
  • Lung Cancer  

    Smoking Statist...  

  • United States  

View report >

Public Health Industry in Canada - Forecast

  • November 2016
    5 pages
  • Public Health  

    Influenza  

    Civil Protectio...  

  • Canada  

View report >

Related Market Segments :

Influenza

ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.